The atrial secondary tricuspid regurgitation is associated to more favorable outcome than the ventricular phenotype.
atrial fibrillation
atrial secondary tricuspid regurgitation
heart failure hospitalizations
prognosis
secondary tricuspid regurgitation
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
08
2022
accepted:
15
11
2022
entrez:
16
12
2022
pubmed:
17
12
2022
medline:
17
12
2022
Statut:
epublish
Résumé
We sought to evaluate the differences in prognosis between the atrial (A-STR) and the ventricular (V-STR) phenotypes of secondary tricuspid regurgitation. Consecutive patients with moderate or severe STR referred for echocardiography were enrolled. A-STR and V-STR were defined according to the last ACC/AHA guidelines criteria. The primary endpoint was the composite of all-cause death and heart failure (HF) hospitalizations. A total of 211 patients were enrolled. The prevalence of A-STR in our cohort was 26%. Patients with A- STR were significantly older and with lower NYHA functional class than V-STR patients. The prevalence of severe STR was similar (28% in A-STR vs. 37% in V-STR, Almost one-third of patients referred to the echocardiography laboratory for significant STR have A-STR. A-STR patients had a lower incidence of the combined endpoint than V-STR patients. Moreover, while TR severity was the only independent factor associated to outcome in A-STR patients, TR severity and RV function were independently associated with outcome in V-STR patients.
Identifiants
pubmed: 36523369
doi: 10.3389/fcvm.2022.1022755
pmc: PMC9744784
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1022755Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 Gavazzoni, Heilbron, Badano, Radu, Cascella, Tomaselli, Perelli, Caravita, Baratto, Parati and Muraru.
Déclaration de conflit d'intérêts
Author MG receives personal fees from Abbot Vascular. Authors DM and LB were members of the speaker bureau of GE Healthcare and Philips Medical Systems, and received research support from GE Healthcare, Philips Medical Systems, and EsaOte. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer DM and handling editor declared their shared affiliation.
Références
Echocardiography. 2012 Feb;29(2):140-6
pubmed: 22067002
JACC Cardiovasc Imaging. 2019 Mar;12(3):433-442
pubmed: 30121261
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Int J Cardiol. 2016 Nov 15;223:93-94
pubmed: 27532240
Eur Heart J Cardiovasc Imaging. 2021 May 10;22(6):660-669
pubmed: 33387441
J Cardiovasc Ultrasound. 2015 Sep;23(3):136-42
pubmed: 26446397
Circ Cardiovasc Interv. 2017 Jul;10(7):
pubmed: 28698289
Circ J. 2018 Apr 25;82(5):1451-1458
pubmed: 29553091
J Am Soc Echocardiogr. 2019 Feb;32(2):238-247
pubmed: 30459122
Eur J Echocardiogr. 2010 May;11(4):307-32
pubmed: 20435783
Circulation. 2008 Apr 1;117(13):1717-31
pubmed: 18378625
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371
pubmed: 28314623
Am J Cardiol. 2006 Jul 15;98(2):236-42
pubmed: 16828600
Am J Cardiol. 2021 Jun 1;148:138-145
pubmed: 33667451
Circulation. 2019 Jul 16;140(3):196-206
pubmed: 31117814
Circulation. 2019 Sep 9;140(10):836-845
pubmed: 31185724
Circulation. 2021 Feb 2;143(5):e72-e227
pubmed: 33332150
Eur Heart J Cardiovasc Imaging. 2020 Oct 1;21(10):1068-1078
pubmed: 32756989
Int J Cardiol. 2013 Sep 30;168(2):707-15
pubmed: 23647591
J Am Soc Echocardiogr. 2021 Jun;34(6):585-594.e1
pubmed: 33440232
Circ Cardiovasc Imaging. 2019 Mar;12(3):e008666
pubmed: 30879327
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
EuroIntervention. 2021 Nov 19;17(10):791-808
pubmed: 34796878
Eur Heart J Cardiovasc Imaging. 2022 Jun 21;23(7):930-940
pubmed: 34747460
JACC Cardiovasc Imaging. 2019 Mar;12(3):500-515
pubmed: 30846124
Eur Heart J Cardiovasc Imaging. 2012 Jan;13(1):1-46
pubmed: 22275509
Eur Heart J Cardiovasc Imaging. 2020 Jul 1;21(7):747-755
pubmed: 32372089
Eur Heart J Cardiovasc Imaging. 2014 May;15(5):500-8
pubmed: 24145456
Eur Heart J Cardiovasc Imaging. 2018 Jun 1;19(6):591-600
pubmed: 29596561
Int J Cardiol. 2022 Oct 15;365:140-147
pubmed: 35853500
Circ Cardiovasc Imaging. 2017 Jan;10(1):
pubmed: 28073806
Circulation. 1990 Sep;82(3):792-7
pubmed: 2144217
BMC Cardiovasc Disord. 2020 Oct 6;20(1):433
pubmed: 33023481
Eur Heart J Cardiovasc Imaging. 2022 Apr 18;23(5):e171-e232
pubmed: 35292799
Mayo Clin Proc. 2019 Oct;94(10):2032-2039
pubmed: 31279540
Eur Heart J Cardiovasc Imaging. 2020 Aug 1;21(8):825-827
pubmed: 32504092
Eur J Cardiothorac Surg. 2021 Oct 22;60(4):727-800
pubmed: 34453161
Eur Heart J Cardiovasc Imaging. 2021 Jan 22;22(2):196-202
pubmed: 32783057
Open Heart. 2021 Feb;8(1):
pubmed: 33589540
J Am Soc Echocardiogr. 2022 Oct;35(10):1028-1036
pubmed: 35817379
J Am Coll Cardiol. 2012 Feb 21;59(8):703-10
pubmed: 22340261
J Heart Lung Transplant. 2013 Jan;32(1):50-5
pubmed: 23164535
J Am Soc Echocardiogr. 2020 Jan;33(1):42-53
pubmed: 31685293
Circ Cardiovasc Imaging. 2012 May 1;5(3):314-23
pubmed: 22447806
Eur Heart J Cardiovasc Imaging. 2022 Oct 20;23(11):1459-1470
pubmed: 35734964
J Clin Med. 2022 Jan 13;11(2):
pubmed: 35054074